"Teaching" Doctors To Push Failing HPV Vaccine

"Teaching" Doctors To Push Failing HPV Vaccine &

Offering Free CME Credits

This activity is supported by an educational grant from Merck & Co., Inc.

Overview

CME

Author(s)/Faculty: Rachel N. Caskey, MD, MaPP; Kenneth A. Alexander, MD, PhD

Source: Healio - Infectious Disease Education Lab

Type: Lecture

Release Date: 2/9/2018

Credit Type: CME

Cost: Free

Articles/Items: 5

Expiration Date: 2/8/2019

Number of Credits: 0.75

Provider:

Vindico Medical Education

This activity is supported by an educational grant from Merck & Co., Inc.

Recent recommendations from the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention suggest timing and dosage changes for the human papillomavirus (HPV) vaccine. Disease prevention remains the most important measure of long-term duration of vaccine efficacy. Concern about vaccine safety and related adverse events has been identified as an important barrier to vaccination, as well as a causative factor for low HPV-vaccination coverage. Recommendation from health care providers is one of the most consistent correlates for HPV vaccination, but efficient communication styles about its prophylaxis is suboptimal. Physicians should be knowledgeable about the recent ACIP recommendations, as well as the safety and efficacy associated with each of the HPV vaccines, to select the most appropriate prophylaxis for their patients. In this CME activity, expert faculty will review the clinical guidelines, the advances in HPV vaccination, and the strategies to increase completion of the HPV vaccination series.

Healio Education Lab

HPV Immunization: Applying Fact versus Fiction

Recent recommendations from the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention suggest timing and dosage changes for the human papillomavirus (HPV) vaccine. Disease prevention remains the most important measure of long-term duration of vaccine efficacy. Concern about vaccine safety and related adverse events has been identified as an important barrier to vaccination, as well as a causative factor for low HPV-vaccination coverage.

Recommendation from health care providers is one of the most consistent correlates for HPV vaccination, but efficient communication styles about its prophylaxis are lacking. Physicians should be knowledgeable about the recent ACIP recommendations, as well as the safety and efficacy associated with each of the HPV vaccines, to select the most appropriate prophylaxis for their patients.

In this CME activity, expert faculty will review the clinical guidelines, the advances in HPV vaccination, and the strategies to increase completion of the HPV vaccination series.

Activity Chair:

Kenneth A. Alexander, MD, PhD

Chief

Division of Allergy, Immunology, Rheumatology, and Infectious Diseases

Nemours Children's Hospital

Orlando, FL

Faculty:

Rachel N. Caskey, MD, MaPP

Associate Professor of Pediatrics and Internal Medicine

University of Illinois at Chicago

Chicago, IL

This continuing medical education activity is provided by

CME Information

Provider Statement: This continuing medical education activity is provided by

.

Support Statement: This activity is supported by an educational grant from Merck & Co., Inc.

Target Audience: The intended audience for this activity is pediatricians and other health care professionals involved in the treatment of patients with HPV.

Learning Objectives: Upon successful completion of this activity, participants should be better able to:

  • Evaluate the latest clinical guidelines regarding the timing of HPV immunizations in preteens and teens.
  • Examine effective strategies to overcome barriers that impede successful completion of the HPV immunization series in both boys and girls.

Example of questions on pre-test...

Vindico Medical Education
Take this activity in our FREE APP!
Vindico Medical Education

This activity is supported by an educational grant from Merck & Co., Inc.

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release February 9, 2018 to February 8, 2019.

hits counter